Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)

BMC Clinical Pharmacology

Volumn 6, Issue , 2006, Pages

  Panchabhai, Tanmay S ^a   Noronha, Shaun F ^a   Davis, Sanish ^a   Shinde, Vishal M ^a   Kshirsagar, Nilima A ^a   Gogtay, Nithya J ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DRUG METABOLITE; LOMAC 20; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INDIA; MALE; NORMAL HUMAN; PHENOTYPE; POPULATION RESEARCH; SINGLE DRUG DOSE;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; MIXED FUNCTION OXYGENASES; MULTIGENE FAMILY; POLYMORPHISM, GENETIC;

EID: 33750730956     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-6-8     Document Type: Article

References (24)

1. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269-96.
2. McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001, 41:101-21.
3. Weinshillboum R: Inheritance and drug response. N Engl J Med 2003, 348:529-537.
4. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348:538-549.
5. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001, 2:9-39.
6. Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S, Nebert DW: Human cytochrome P450 (CYP) alleles a web page for the nomenclature of alleles. [http:www.imm.ki.se/CYPalleles/]. (accessed November 22, 2005)
7. Desta Z, Zhao X, Shin JG, Flockhart DA: Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913-58.
8. Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ: Differences in diazepam pharmacokinetics in Chinese and white Caucasians - relation to body lipid stores. Eur J Clin Pharmacol 1987, 32:211-5.
9. Daly AK: Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004, 4:1733-44.
10. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA: An additional defective allele, CYP2C 19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmocogenetics 1998, 8:129-135.
11. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997, 7:59-64.
12. Herrlin K, Massele AY, Rimoy G, Alm C, Rais M, Ericsson O, Bertilsson L, Gustafsson LL: Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin Pharmacol Ther 2000, 68:189-98.
13. Chang M, Tybring G, Dahl M-L, Götharson E, Sagar M, Seensalu R, Bertilsson L: Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995, 39:511-518.
14. Somogyi AA, Reinhard HA, Bochner F: Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol 1996, 41:175-179.
15. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998, 129:1027-30.
16. Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Okumura K: CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999, 66:528-534.
17. Lamba JK, Dhiman RK, Kohli KK: CYP2C 19 genetic mutations in North Indians. Clin Pharmacol Ther 2000, 68:328-35.
18. Rosemary J, Adithan C, Padmaja N, Shashindran CH, Gerard N, Krishnamoorthy R: The effect of the CYP2C19 genotype on the hydroxylation index of omeprazole in South Indians. Eur J Clin Pharmacol 2005, 61:19-23.
19. Ethical Guidelines for Biomedical Research in Human subjects of the Indian Council of Medical Research. 2000.
20. Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T: Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column. J Chromatogr 1992, 579:299-305.
21. Malhotra KC: Morphological composition of the people of India. J Hum Evol 1978, 7:45-63.
22. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH: Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995, 58:404-11.
23. Balian JD, Sukhova N, Harris JW, Hewett J, Picide L, Goldstein JA, Woosley RL, Flockhart DA: The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995, 57:662-629.
24. Sim SCM, Aklillu E, Edwards RJ, Ahlberg S, Bertilsson L, Ingelman-Sundberg M: Identification of an CYP2C19 allele (CYP2C19*ID) causing enhanced expression. Proceedings Of The International Symposium On Microsomes And Drug Oxidations; 2004 Jul 4-9; Mainz, Germany. Mainz: The Symposium 2004.